Every S-3 that Quoin Pharmaceuticals, Ltd. (QNRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow QNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNRX filings page.
Quoin Pharmaceuticals Ltd. registered up to $150,000,000 in aggregate offering price of ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units for one or more offerings. No securities may be sold until the registration statement is effective, and a sale requires an applicable prospectus supplement. While public float remains below $75.0 million, public primary sales are limited to no more than one-third of public float in any 12-month period; Quoin reported no sales under this limit during the 12 calendar months prior to and including October 27, 2026. Net proceeds are currently intended primarily for working capital and general corporate purposes, subject to any supplement or free writing prospectus.
Quoin describes itself as a late-stage clinical specialty pharmaceutical company with no commercialized products or product revenue to date. Its lead candidate QRX003 is entering pivotal registrational clinical testing for Netherton Syndrome; eight pediatric patients are in a Compassionate Use program, with three additional patients expected to enroll in 2026. The FDA cleared the Peeling Skin Syndrome IND on July 9, 2026, and the company plans to initiate a Phase 2/3 study by the end of 2026.
Quoin Pharmaceuticals Ltd. (QNRX) is registering the resale of up to 9,371,895 American Depositary Shares (ADSs), representing 328,016,325 ordinary shares, issued or issuable to selling shareholders from an August 2026 private placement. The ADSs consist of Offered ADSs, ADSs from Pre-Funded Warrants, and ADSs from Ordinary Warrants. Quoin will not receive proceeds from shareholder resales but could receive up to $19.1 million in cash if all Ordinary Warrants are exercised. As of September 16, 2026, 4,804,161 ADSs were outstanding, and full exercise of the warrants would increase this to 11,730,256 ADSs; ADSs covered by this prospectus and not currently outstanding equal about 144.2% of current ADSs, implying substantial potential dilution. Quoin is a late-stage clinical specialty pharma company, with lead candidate QRX003 in pivotal development for Netherton Syndrome and additional programs in other rare dermatologic and orphan indications.
Quoin Pharmaceuticals Ltd. (QNRX) filed a Form S-3 to register the resale of up to 10,045,455 American Depositary Shares (ADSs) (representing 351,590,925 ordinary shares) by the selling shareholders, from time to time after effectiveness. The company is not offering these ADSs and will not receive proceeds from any resales.
Quoin notes it could receive up to $88.7 million only if the accompanying warrants are exercised for cash. The filing follows an October 2025 private placement that included Closing ADSs, Pre-Funded Warrants and Series H, I, J and K warrants. The company highlights potential dilution; the ADSs covered here (and not currently outstanding) are approximately 1,193% of ADSs outstanding as of the prospectus date.
As context, 838,976 ADSs were outstanding as of November 3, 2025. The registration fulfills contractual obligations under a registration rights agreement and allows selling holders to dispose of their ADSs via various permitted methods.